Literature DB >> 26112250

Evaluation of Approaches to Deal with Low-Frequency Nuisance Covariates in Population Pharmacokinetic Analyses.

Chakradhar V Lagishetty1, Stephen B Duffull2.   

Abstract

Clinical studies include occurrences of rare variables, like genotypes, which due to their frequency and strength render their effects difficult to estimate from a dataset. Variables that influence the estimated value of a model-based parameter are termed covariates. It is often difficult to determine if such an effect is significant, since type I error can be inflated when the covariate is rare. Their presence may have either an insubstantial effect on the parameters of interest, hence are ignorable, or conversely they may be influential and therefore non-ignorable. In the case that these covariate effects cannot be estimated due to power and are non-ignorable, then these are considered nuisance, in that they have to be considered but due to type 1 error are of limited interest. This study assesses methods of handling nuisance covariate effects. The specific objectives include (1) calibrating the frequency of a covariate that is associated with type 1 error inflation, (2) calibrating its strength that renders it non-ignorable and (3) evaluating methods for handling these non-ignorable covariates in a nonlinear mixed effects model setting. Type 1 error was determined for the Wald test. Methods considered for handling the nuisance covariate effects were case deletion, Box-Cox transformation and inclusion of a specific fixed effects parameter. Non-ignorable nuisance covariates were found to be effectively handled through addition of a fixed effect parameter.

Entities:  

Keywords:  Box-Cox transformation; case deletion and pharmacometrics; fixed effect parameter; nuisance covariate

Mesh:

Year:  2015        PMID: 26112250      PMCID: PMC4627442          DOI: 10.1208/s12248-015-9793-x

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  15 in total

1.  Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study.

Authors:  K G Kowalski; M M Hutmacher
Journal:  Stat Med       Date:  2001-01-15       Impact factor: 2.373

2.  Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences.

Authors:  Jogarao V S Gobburu; John Lawrence
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

3.  Some alternatives to asymptotic tests for the analysis of pharmacogenetic data using nonlinear mixed effects models.

Authors:  Julie Bertrand; Emmanuelle Comets; Marylore Chenel; France Mentré
Journal:  Biometrics       Date:  2011-11-03       Impact factor: 2.571

4.  Estimating risk from underpowered, but statistically significant, studies: was APPROVe on TARGET?

Authors:  A La Caze; S Duffull
Journal:  J Clin Pharm Ther       Date:  2010-12-12       Impact factor: 2.512

5.  Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses.

Authors:  Ron J Keizer; Anthe S Zandvliet; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  AAPS J       Date:  2012-05-31       Impact factor: 4.009

6.  Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype.

Authors:  Nitin Kaila; Robert J Straka; Richard C Brundage
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-12       Impact factor: 2.745

Review 7.  What do we learn from repeated population analyses?

Authors:  Stephen B Duffull; Daniel F B Wright
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

8.  Semiparametric distributions with estimated shape parameters.

Authors:  Klas J F Petersson; Eva Hanze; Radojka M Savic; Mats O Karlsson
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

9.  Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.

Authors:  Julie Bertrand; Emmanuelle Comets; Céline M Laffont; Marylore Chenel; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-27       Impact factor: 2.745

10.  Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach.

Authors:  Cédric Laouénan; Jeremie Guedj; France Mentré
Journal:  BMC Med Res Methodol       Date:  2013-04-25       Impact factor: 4.615

View more
  5 in total

1.  Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation.

Authors:  Satoshi Ueshima; Daiki Hira; Chiho Tomitsuka; Miki Nomura; Yuuma Kimura; Takuya Yamane; Yohei Tabuchi; Tomoya Ozawa; Hideki Itoh; Minoru Horie; Tomohiro Terada; Toshiya Katsura
Journal:  AAPS J       Date:  2019-06-24       Impact factor: 4.009

2.  Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients.

Authors:  Yu-Si Chen; Zi-Qi Liu; Rong Chen; Lei Wang; Ling Huang; Xiao Zhu; Tian-Yan Zhou; Wei Lu; Ping Ma
Journal:  Acta Pharmacol Sin       Date:  2017-05-29       Impact factor: 6.150

3.  Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites.

Authors:  Zheng Liu; Jennifer H Martin; Winston Liauw; Sue-Anne McLachlan; Emma Link; Anetta Matera; Michael Thompson; Michael Jefford; Rod J Hicks; Carleen Cullinane; Athena Hatzimihalis; Ian Campbell; Simone Crowley; Phillip J Beale; Christos S Karapetis; Timothy Price; Mathew E Burge; Michael Michael
Journal:  Eur J Clin Pharmacol       Date:  2021-09-04       Impact factor: 2.953

4.  External evaluation of population pharmacokinetic models for voriconazole in Chinese adult patients with hematological malignancy.

Authors:  Weikun Huang; You Zheng; Huiping Huang; Yu Cheng; Maobai Liu; Nupur Chaphekar; Xuemei Wu
Journal:  Eur J Clin Pharmacol       Date:  2022-06-28       Impact factor: 3.064

5.  Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.

Authors:  Satoshi Ueshima; Daiki Hira; Yuuma Kimura; Ryo Fujii; Chiho Tomitsuka; Takuya Yamane; Yohei Tabuchi; Tomoya Ozawa; Hideki Itoh; Seiko Ohno; Minoru Horie; Tomohiro Terada; Toshiya Katsura
Journal:  Br J Clin Pharmacol       Date:  2018-04-16       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.